Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.
Over a period of 17 years, from 1992 to 2009, around 90,000 individuals underwent research. The following year, 2009 saw the EMEA giving its approval for SCINTIMUN's sale across all European countries.